PATENT CLAIM ANALYSIS

Application Number: 16311623
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-08
Patent Classification: ["544", "324000"]

Abstract:
The present application belongs to the field of medicinal chemistry, and relates to crystals of an aniline pyrimidine compound serving as an EGFR inhibitor. Specifically, the present application relates to crystal A, crystal B and crystal C of N-(2-((2-(dimethyl amino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-base)pyrimidine-2-base amino)phenyl)acrylamide (formula I) hydrochloride, and also relates to the method for preparing the crystal A, the crystal B and the crystal C, a crystal composition comprising the crystal A, the crystal B, and the crystal C, a pharmaceutical composition comprising the crystal A, the crystal B and the crystal C or the crystal composition thereof, and medical uses thereof. The crystal A, the crystal B and the crystal C in the present application has the advantages of high purity, high crystallization degree, good stability and the like.

Claim (Index 8):
The crystal B of the hydrochloride of the compound represented by formula I according to  claim 7 , wherein its DSC spectrum has a peak at 259\u00b0 C.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 2.47887
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16310369', '16059890', '15748283', '13003216', '14448070']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8028605368772755
- 35 USC 102 Novelty (BERT): 0.5297884464885498
- Combined Prediction Score: 0.7755533278384029
- Mean Citation Score: 312.12674
- Max Citation Score: 360.77982
- Similarity Product: 230.11948957981463

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test